Loading
Life sciences · Phase 2/3 Trial
ClinicalTrials.gov · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2/3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07063745). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 590 participants (ESTIMATED). Conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion. Interventions: DRUG: BMS-986504; DRUG: Pembrolizumab; OTHER: Placebo; DRUG: Cisplatin; DRUG: Carboplatin; DRUG: Pemetrexed; DRUG: Paclitaxel; DRUG: Nab-paclitaxel. Primary outcome measures: Progression-free survival (PFS) by RECIST v1.1 , Up to 2 years; PFS by RECIST v1.1 per BICR , Up to 5 years; Overall Survival (OS) , Up to 5 years. Brief summary: The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion